



www.genfit.com

## GENFIT: CONVERSIONS INTO SHARES OF 10 BONDS OCA2012-2

**Lille (France), Boston (Massachusetts, United States), April 24<sup>th</sup>, 2013** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversions into shares of 10 bonds OCA2012-2 in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1<sup>st</sup> and 2<sup>nd</sup> resolutions of the Extraordinary Shareholders' Meeting held on December 18<sup>th</sup>, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested this conversion of 10 bonds OCA2012-2 on April 23<sup>th</sup>, 2013 for a value of €100,000.

The conversion into 17,861 new shares was performed at a conversion rate of €5.60, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (April 16<sup>th</sup>, 2013- April 22<sup>th</sup>, 2013) prior to the conversion request.

As a result of this conversion reserved to the Bondholder:

- The social capital of GENFIT has increased from €5,079,246 to €5,083,711.25 ;
- The number of shares representing the social capital of GENFIT has increased by 17,468, from 20,316,984 to 20,334,845 shares;
- The amount of the 7<sup>th</sup> installment of the bond loan agreement that remains to be converted is €900,000.

### About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### Contacts:

#### GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board  
Ph. +333 2016 4000

#### MILESTONES – Press Relations

Bruno Arabian Ph. +33 1 7544 8740 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)